Partnering with Constantia Flexibles for augmented reality Partnering with Constantia Flexibles for augmented reality Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio
commitments to sustainable development commitments to sustainable development On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
FDA Grants Breakthrough Status to Schizophrenia Treatment FDA Grants Breakthrough Status to Schizophrenia Treatment Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
The first liquid solution for hypertension in cats The first liquid solution for hypertension in cats Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
Partnering-with-google-in-quantum-computing Partnering-with-google-in-quantum-computing New cooperation with Google explores the potentials of quantum computing for pharma R&D.
How Boehringer Ingelheim is Supporting Grass Roots Innovation How Boehringer Ingelheim is Supporting Grass Roots Innovation Our Grass Roots activities support life-science innovators with mentoring and networking opportunities.
About Boehringer Ingelheim Partnering Days About Boehringer Ingelheim Partnering Days Find out more about our partnering days and how we can work together to accelerate your science
Awards & International Recognition| Bioxcellence | Boehringer Ingelheim Awards & International Recognition| Bioxcellence | Boehringer Ingelheim Explore Bioxcellence's global recognition, showcasing our prestigious awards & certifications. Witness our commitment to excellence in biopharmaceuticals!
Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim Meet BioXcellence - your trusted partner for top-quality biopharmaceutical development & manufacturing. Experience our world-class service. Contact us.
New production center for Veterinary Public Health New production center for Veterinary Public Health Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
collaboration criving innovation collaboration criving innovation In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
clinical-collaboration-with-Amgen clinical-collaboration-with-Amgen Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
2018 Animal Welfare Medals 2018 Animal Welfare Medals 2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Fast-Track-Designation-NASH Fast-Track-Designation-NASH Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Making-more-health-together-2021 Making-more-health-together-2021 1,200 participants from around the world join virtual convention on November 11-12
GastroGard the first imported equine drug in China GastroGard the first imported equine drug in China GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
European Metacam® indication expanded to guinea pigs European Metacam® indication expanded to guinea pigs Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
History video History video Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
Jens Barthelmes Jens Barthelmes My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
World Patient Safety Day 2021 World Patient Safety Day 2021 As a sign of support for World Patient Safety Day, Boehringer Ingelheim lights up buildings in orange.
Our Venture Fund on the search for groundbreaking trends Our Venture Fund on the search for groundbreaking trends The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers